A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

NCT03080987 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-64179375 0.3 mg/kg
DRUG: JNJ-64179375 1.0 mg/kg
DRUG: JNJ-64179375 2.5 mg/kg
OTHER: Placebo
DRUG: JNJ-64179375 (Dose to be Determined)

Sponsor

Janssen Research & Development, LLC